Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Key claim: A phase I/II trial is evaluating azacitidine combined with quizartinib to determine safety, optimal dosing, and efficacy in MDS or MDS/MPN patients harboring FLT3 or CBL mutations.
Abstract
This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine and quizartinib may help to control myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm.
Why this matters
MDS/MPN overlap syndromes have historically lacked mutation-directed prospective therapy, with treatment extrapolated from MDS or MPN paradigms. Layering quizartinib onto azacitidine for FLT3- or CBL-mutated disease introduces a second FLT3-targeted prospective option in this subtype (alongside the aza/venetoclax/gilteritinib triplet) and is the first to formally include CBL-mutant overlap disease as an enrollment criterion. This sharpens the molecularly stratified treatment landscape for a subtype where genotype-driven trials remain rare.